AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01622634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher CARB Diet
Description: Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
Study NCT04585009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Study NCT04585009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
Study NCT00804687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
Study NCT03288246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: point-of-care viral load test
Description: A point-of-care viral load test returns viral load test results within 90 minutes.
Study NCT01226290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VizAblate System
Description: VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.
Study NCT04157387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyriax inferior capsular stretching + Manual Therapy
Description: Electro-therapy 10mins Manual therapy : Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Active ROM exercises : 10 reps x 3 sets Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each) Cyriax inferior capsular stretching
Study NCT04157387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Before starting capsule stretching technique, Analgesic short-wave diathermy may be given for 10 minutes.~Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each)
Study NCT01773421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7820
Description: FOOD EFFECT STUDY:~Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8.
Study NCT01773421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7820
Description: MTD DETERMINATION FOR BID DOSING SCHEDULE~The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation, the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID.
Study NCT00808444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A (different lots)
Description: Intramuscular injection, 3 doses
Study NCT00808444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore
Study NCT00808444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, only for Visit 2 in Singapore
Study NCT00808444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Oral, 2 doses
Study NCT02327260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video + Motivational interview for CR participation
Description: Patients will be shown a 9 minute video that highlights actual CR patients discussing barriers they overcame to participate in CR, and introductions to the CR staff. The brief, phone-based motivational interview will focus on increasing motivation to participate in CR.
Study NCT02327260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview for medication adherence
Description: The brief, phone-based motivational interview will focus on increasing motivation to adhere to prescribed cardioprotective medications.
Study NCT04213404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle
Study NCT04213404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
Study NCT01936389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286
Study NCT03526289 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GIP1-42 infusion
Description: 5-hour GIP1-42 infusion (time point 0-300 minutes)
Study NCT03526289 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5-hour infusion of saline (placebo) (time point 0-300 minutes)
Study NCT01809548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early intervention group
Description: solid food will be introduced between week 10 and 12
Study NCT01809548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late intervention group
Description: solid food is introduced between 16-18th week of gestation corrected for prematurity
Study NCT06031077 — intervention group
Intervention type: PROCEDURE
Intervention: cardiac catheterization
Description: An observational, retrospective study will be carried out. Roughly 111 patients were registered at EWMSC and Cardiac Angiograms were done via approached through the left radial access between January 2020 and June 2021 at EWMSC. However since 2021 Cardiac Angiograms were also done via the anatomical snuff box. This study seeks to compare the results of Cardiac Angiograms vs Left Radial Access and the Anatomical Snuff box.
Study NCT02597855 — intervention group
Intervention type: DRUG
Intervention: Aflibercept
Description: Total 4 times of intravitreal aflibercept injection was performed
Study NCT02597855 — intervention group
Intervention type: DRUG
Intervention: Indocyanine green angiography (intraveonus indocyanine green dye)
Description: At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
Study NCT00746174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone 8mg PO daily for 16 weeks
Study NCT00746174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet PO daily for 16 weeks
Study NCT01487421 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
Study NCT01487421 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
Study NCT04585009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Study NCT01373827 — intervention group
Intervention type: DEVICE
Intervention: VASERShape MC1
Description: Use of the VASERShape MC1 device as part of routine practice
Study NCT01245907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied relaxation
Description: Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
Study NCT03785548 — intervention group
Intervention type: OTHER
Intervention: Usage of a mirror
Description: using a mirror during the pelvic examination
Study NCT01556308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Taking of liquid and top of blisters
Description: the liquid and the top of blisters will be took.
Study NCT03586700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao zhong fang granules
Description: Chinese medicine Xiao zhong fang was Professor Sun Chengxiang's experience formula in Massage Department of Dongzhimen Hospital. The function of the formula is to activate blood circulation and dredge collaterals, tonifying kidney and promoting dampness to soothe the liver and nourish tendons.
Study NCT03586700 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Short wave infrared radiation
Description: Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
Study NCT03586700 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short wave infrared radiation
Description: Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
Study NCT03586700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Xiao zhong fang granules
Description: Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.
Study NCT02419456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2048A IVR (Low Dose)
Description: Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
Study NCT02419456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2048A IVR (Original Dose)
Description: Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
Study NCT04000464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLIPP
Description: Diabetes Prevention program and Comprehensive Lifestyle Improvement Program consisting of low calorie diet, physical activity, sleep optimization and stress management
Study NCT00558857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Substrate Mapping-guided ablation
Description: Radiofrequency ablation
Study NCT02378571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication adherence telemonitoring
Description: The member of the study team will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
Study NCT03265977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56:IC31
Description: The H56 antigen is a fusion protein created from 3 Mtb antigens: antigen 85B (Ag85B), ESAT-6, and Rv2660c.
Study NCT03265977 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT03018834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAKINRA 100 mg/daily subcutaneously
Description: ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
Study NCT03018834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
Study NCT06387771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Tolcapone (Film-coated tablet) 200 mg orally every 8 hours for 7 days
Study NCT01387022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir, lamivudine and efavirenz
Description: Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
Study NCT01387022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir, lamivudine and efavirenz
Description: Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
Study NCT04470557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: D-dimer,CBC.ESR,CRP,
Description: Complete blood count (for patients and control subjects): was done on CELL-DYN 3700 (Abbott-Germany) and blood film was stained by leishman staining, the morphology of red blood cells. CRP titre estimation by latix method .ESR erythrocyte sedimentation rate estimation (1:5) by Westerngreen tube method.
Study NCT04470557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liver function tests ,serum ferritin and PCR for COVID-19 .
Description: Serum ferritin was performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, Germany),~• Liver function tests ( aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase) and kidney funcrion were performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, G ermany),
Study NCT00817960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: The effect of ritalin on postural stability of old adults (65 years old and over) will be measured using RCT study design
Study NCT00429234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks.
Study NCT00429234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Starting dose of 800 mg/m\^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
Study NCT00696020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL/tiotropium bromide fixed dose combination
Description: BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
Study NCT00696020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
Study NCT00696020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat® Inhaler
Study NCT01545830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 (cholecalciferol)
Description: Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
Study NCT01545830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 (cholecalciferol)
Description: Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
Study NCT03260465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: seleXys PC
Description: Total hip arthroplasty using the seleXys PC cup
Study NCT03260465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RM
Description: Total hip arthroplasty using the RM cup
Study NCT00233194 — intervention group
Intervention type: PROCEDURE
Intervention: Observational follow-up study of adenotonsillectomy
Description: Studies of sleep, behavior, cognition, and daytime sleepiness
Study NCT01232426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodegradable Meniscus Arrow®
Description: Closed reduction of the Mallet fracture and fixation with 1 biodegradable meniscus Arrow®
Study NCT01232426 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mallet splint
Description: Conservative treatment of the Mallet fracture with the traditional Mallet splint.
Study NCT03920904 — intervention group
Intervention type: OTHER
Intervention: Collection of blood samples
Description: Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
Study NCT02762773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-dissection of inferior rectus sheath
Description: Non-dissection of inferior rectus sheath
Study NCT02762773 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Dissection of inferior and superior aspect of the rectus sheath
Study NCT02723045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Lichtenstein Hernioplasty
Study NCT02723045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TEP Hernioplasty
Study NCT02969408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate
Description: Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
Study NCT02131857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active interventional program based on Mindfulness training
Description: active interventional program based on Mindfulness training
Study NCT04154579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeRe We Arts
Description: Art Therapy interventions to promote health, resilience \& well-being will discussed; \& experiences such as key chain making, collaging on journal covers, creating sculpture garden will be utilized. Music therapy interventions such as lyric discussion, singing, instrument playing, \& music-assisted relaxation techniques will be utilized; \& discussion of use of music to elicit positive physical \& emotional responses will be held. Drums Alive (drumming \& movement) will be used to promote physical activity. Art appreciation will include discussion of public art forms. Journaling will include different techniques for journaling, writing poetry, etc. Theater games such as Password, Press Conference, Props Only, \& Draw What You Hear will be utilized. Chair yoga will be introduced as a form of exercise. Education will be provided on the various topics.
Study NCT04154579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HeRe We Ed
Description: Educational components and some experiential components will be utilized to educate the participants on health, resilience, well-being, nutrition, healthy eating, weight management, eating disorders, obesity, exercise, physical activity, sleep hygiene and the importance of sleep, mental health, stress management, the importance of improving life satisfaction, holistic approaches, wellness, integrative medicine, complementary and alternative medicine, chronic illness, chronic pain, methods for dealing with chronic versus acute illnesses, changing behaviors and/or maintaining healthy behaviors in order to promote health and stay out of the hospital, and navigating the healthcare system. Specific experiential components will include Chair Yoga and Stress Management Techniques.
Study NCT01758627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Description: PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
Study NCT01009840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV busulfan
Description: PK-directed dosing of IV busulfan for 4 days
Study NCT01009840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Single IV bortezomib at a dose of 1.3 mg/m\^2.
Study NCT01009840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplant (HSCT)
Study NCT05035121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk supplement
Description: Intervention groups provided 200 mL long life milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
Study NCT05035121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy milk supplement
Description: Intervention groups provided 200 mL long life soy milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
Study NCT04022733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moderate neuromuscular block
Description: maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
Study NCT04022733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
Study NCT03480464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-technology to increase physical activity
Description: The application will send daily reminders to register and notices with information about the health benefit of physical activity, medication, supplementary vitamins and diet after surgery
Study NCT01050153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin sodium
Description: Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory
Study NCT01050153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium/aspirin
Description: Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily) po.
Study NCT05035121 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: resistance exercise
Description: The participants joined the resistance exercise training program, three times per week (30 min/time)
Study NCT05035121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: The participants joined the resistance exercise training program, three times per week (30 min/time)